BridgeBio Oncology Therapeutics (BBOT) Net Cash Flow (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Net Cash Flow of -$321.0 million for Q1 2026, down 815.81% sequentially from -$35.1 million in Q4 2025, and down 6826.19% YoY from $4.8 million in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Net Cash Flow (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Net Cash Flow for 3 years, with the latest figure at -$321.0 million in Q1 2026.
- Quarterly Net Cash Flow fell 6826.19% year-over-year to -$321.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$408.1 million (down 1782.76% YoY) and the FY2025 annual result came in at $342.8 million, up 1015.53% from the prior year.
- Net Cash Flow fell to -$321.0 million in Q1 2026 per BBOT's latest filing, from -$35.1 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $18.6 million in Q2 2025 and troughed at -$321.0 million in Q1 2026.
- A 3-year average of -$42.4 million and a median of -$29099.0 in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2025 and 2026: Net Cash Flow soared 63901.0% in 2025, then slumped 6826.19% in 2026.
- Over 3 years, Net Cash Flow stood at $10.6 million in 2024, then sank by 431.54% to -$35.1 million in 2025, then tumbled by 815.81% to -$321.0 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$321.0 million, -$35.1 million, and -$70.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.41 Mn |
| Jun 30, 2026 | 1.41 Mn |
| Mar 31, 2026 | -321.03 Mn |
| Mar 31, 2026 | -321.03 Mn |
| Dec 31, 2025 | -35.05 Mn |
| Dec 31, 2025 | -35.05 Mn |
| Sep 30, 2025 | -70.63 Mn |
| Sep 30, 2025 | -70.63 Mn |
| Jun 30, 2025 | 18.57 Mn |
| Jun 30, 2025 | 18.57 Mn |
| Mar 31, 2025 | -4.64 Mn |
| Mar 31, 2025 | -4.64 Mn |
| Dec 31, 2024 | 10.57 Mn |
| Dec 31, 2024 | 10.57 Mn |
| Sep 30, 2024 | 18.35 Mn |
| Sep 30, 2024 | 18.35 Mn |
| Jun 30, 2024 | -29,099.00 |
| Jun 30, 2024 | -29,099.00 |
| Mar 31, 2024 | 1.84 Mn |
| Mar 31, 2024 | 1.84 Mn |